Congenital methaemoglobinaemia Type I in a Turkish infant due to a novel mutation, Pro144Ser, in NADH-cytochrome b5 reductase.
A baby centrally cyanosed from birth was investigated for a congenital cardiac defect. Echocardiography and angiography revealed patent foramen ovale without any other cardiac abnormality. Congenital methaemoglobinaemia was considered as the methaemoglobin level was 27%, suggesting either Hb M or a deficiency of the NADH-cytochrome b5 reductase (cytb5r) enzyme. Measurement of the cytb5r enzyme activity of this patient indicated a reduced level of 7.3 IU/g Hb (normal range 11.5-26.9 IU/g Hb). Sequencing the DIA 1 gene that encodes cytb5r revealed a novel C403T base change, predicting a proline to serine change at codon 144. This amino-acid change is not located in the enzyme's active site and does not cause loss of function. Instead it results in reduced stability of the enzyme and development of the less severe or Type I form of recessive congenital methaemoglobinaemia. The infant was started on daily ascorbic acid treatment. She has very mild cyanosis and normal growth and developmental parameters on follow-up at 10 months of age.
Percy
Melanie J
MJ
Department of Haematology, Belfast City Hospital, Belfast, Northern Ireland, UK. melanie.percy@bll.n-i.nhs.uk
Oren
Hale
H
Savage
Geraldine
G
Irken
Gülersu
G
D019943:Amino Acid Substitution; D001205:Ascorbic Acid / Q000627:therapeutic use; D042966:Cytochrome-B(5) Reductase / Q000235:genetics*; D005260:Female; D006801:Humans; D007223:Infant; D008708:Methemoglobinemia / Q000151:congenital / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D020125:Mutation, Missense; D011392:Proline; D012694:Serine; D016896:Treatment Outcome; D014421:Turkey
D012694:Serine; D011392:Proline; D042966:Cytochrome-B(5) Reductase; D001205:Ascorbic Acid